2023年7月27日

讀全文·3分鍾讀觀察名單中洛杉磯CA - (NewMediaWire)——7月25日,2023 - (InvestorBrandNetwork通過NewMediaWire) -伊本,多方麵的金融新聞,內容創作和出版公司,利用公共和私人公司優化投資者認識和認可。Genprex(納斯達克:GNPX)基因治療臨床分期公司專注於開發改變治療癌症和糖尿病的患者,已經關閉了其先前宣布注冊直接提供。7425744股的發行是由該公司的普通股認股權證購買7425744股普通股;在提供healthcare-focused機構投資者以每股1.01美元的普通股和相應的保證,這是在納斯達克市場定價規則。根據公告,提供了一個估計7。5百萬美元,之前放置提供代理費用和其他費用中扣除;H.C.溫賴特& co .)擔任獨家代理提供的布置。公司打算Genprex使用封閉的淨收益提供營運資本和一般企業用途。查看完整的新聞稿,請訪問https://ibn。調頻/ Z0rZn Genprex Inc . Genprex基因治療臨床分期公司專注於發展改變治療癌症和糖尿病患者。Genprex的技術設計管理抗病基因提供新的治療與癌症和糖尿病患者群體大,目前治療方法有限。 Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its proprietary, nonviral ONCOPREX(R) Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that are deficient in the tumor. The company's lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer ("NSCLC") and small cell lung cancer ("SCLC"). Each of Genprex's three lung cancer clinical programs have received a fast-track designation from the Food and Drug Administration. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus ("AAV") vector to deliver Pdx1 ("Pdx1") and MafA ("MafA") genes directly to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-003 for type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, please visit the company's website at www.Genprex.com . Story continues NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company's newsroom at http://ibn.fm/GNPX About IBN IBN has introduced 50+ distinct investor-focused brands over the last 15+ years and has leveraged these unique brands to amass a collective audience of millions of social media followers. In conjunction with 5,000+ syndication partnerships, IBN's broad-based investor-facing brands help fulfill the diverse demands and needs of our rapidly growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, harnessing the energy and experience of our team of specialized experts to exceed the expectations of each of our client-partners. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer Corporate Communications